Patent ID: 6426220
Filing Date: 2002-07-30
Classification: A61K,C12N,Y02P

Abstract:
An antisense compound 8 to 30 nucleobases in length targeted to nucleobases 1 through 20 or nucleobases 73 through 92 of a 5â€² untranslated region, nucleobases 137 through 156, nucleobases 181 through 200, nucleobases 223 through 242, nucleobases 267 through 286, nucleobases 310 through 329, nucleobases 331 through 350, nucleobases 354 through 373, nucleobases 378 through 417, nucleobases 439 through 475, nucleobases 483 through 537, nucleobases 541 through 574, nucleobases 583 through 663, nucleobases 666 through 685, nucleobases 689 through 727, nucleobases 736 through 770, nucleobases 777 through 833, nucleobases 836 through 896, nucleobases 939 through 973, nucleobases 979 through 998, nucleobases 1014 through 1033, nucleobases 1039 through 1075, nucleobases 1083 through 1117, nucleobases 1124 through 1160, nucleobases 1163 through 1202, nucleobases 1210 through 1244, nucleobases 1248 through 1305, or nucleobases 1311 through 1330 of a coding region, nucleobases 1344 through 1381 of a stop codon region or nucleobases 1394 through 1426, nucleobases 1435 through 1454, nucleobases 1467 through 1486, nucleobases 1558 through 1592, nucleobases 1614 through 1633, nucleobases 1679 through 1698, nucleobases 1702 through 1755, nucleobases 1835 through 1870, nucleobases 1877 through 1911, or nucleobases 1920 through 1939 of a 3â€² untranslated region of human calreticulin (SEQ ID NO: 3), wherein said antisense compound specifically hybridizes with one of said regions and inhibits the expression of human calreticulin (SEQ ID NO: 3).